AbbVie Just Won FDA Approval for a Once-Daily Parkinson's Pill. Here's Why It Matters More Than You Think.

Impact · against what's priced in

The FDA approval of Juvmo provides commercial validation for the Cerevel acquisition but is not a significant catalyst given the drug's small projected revenue relative to AbbVie's scale. While it supports the growth of the neuroscience portfolio, the projected $1.4 billion peak revenue by 2040 is modest compared to the growth rates the market already requires to offset Humira's erosion.

ABBV+0.10

Already priced in

The price assumes

Neuroscience portfolio revenue of approximately $12.7 billion, including 20.3% year-over-year growth.